Emerging Therapeutic Strategies in the Management of Anemia in Patients with CKD

Released On
February 24, 2020

Expires On
February 24, 2021

Media Type
Internet

Completion Time
45 minutes

Specialty
Cardiology, Education, Neurology, Other Nephrologists, Primary Care

 

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Integrity Continuing Education, Inc.

 

Supported by an independent educational grant from AstraZeneca Pharmaceuticals, LP.

Credit Available

  • Physicians — maximum of 0.75 AMA PRA Category 1 Credit(s)

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity is intended for nephrology specialty HCPs that manage patients with anemia in CKD.

Program Overview

Patients with CKD and anemia experience substantially increased burdens to morbidity and mortality. The use of erythropoiesis-stimulating agents (ESAs) and iron supplementation are the mainstays of therapy, yet ESA has been associated with increased cardiovascular adverse events. Increased understanding of hypoxia-inducible factors (HIFs) have led to the development of novel therapies, HIF-PHIs, that work by simulating hypoxia in cells, thereby stimulating EPO synthesis and improving iron metabolism and mobilization through recduced hepcidin levels. Four HIF-PHIs are currently undergoing late-stage development, with one agent already approved to treat anemia in patients with CKD in China. It is important that healthcare providers are updated on the clinical trial data of these novel therapies so they are better prepared to integrate these agents in to clinical practice upon FDA approval.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe the prevalence of and burden associated with anemia in patients with chronic kidney disease (CKD), particularly those who are hyporesponsive to Erythropoietin Stimulating Agents (ESA) therapy
  • Discuss the pathogenic mechanisms involved in anemia associated with CIKD, including the roles of inflamation, hepcidin, and the HIF pathway
  • Explain the clinical utility of measuring hepcidin levels in patiens with anemia and CKD
  • Review outcomes from clinical trials evaluating the use of HIF-PHIs to treat anemia in patients with CKD

Faculty

FACULTY NAME and TITLE



Andrew Howard, MD, FACP
Metropolitan Nephrology Associates
Senior Consultant to the CMO
Fresenius Kidney Care

Physician Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physician Credit Designation

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Andrew Howard, MD, FACP

  • Consulting: Fresenius Kidney Care

The Integrity Continuing Education, Inc. planners have nothing to disclose.

Instructions for Participation and Credit

There are no fees for participating and receiving CME credit for this activity. During the period of February 24, 2020 through February 24, 2021 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pre-test
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and AstraZeneca Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Contact Information

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or information@integrityce.com

If you have any questions relating to your certificate or other issues with this activity, please contact FreeCME.